Paeds SAQs · genetics-dysmorphology-and-metabolism
Fragile X syndrome — formative SAQs
Formative SAQs on recognising fragile X syndrome, confirming the molecular diagnosis with FMR1 PCR plus methylation analysis, classifying the CGG-repeat allele, building comorbidity-driven multidisciplinary support, and running cascade testing of the wider family.
On this page
Study tools
Target exams
SAQ 1 (10 marks)
A three-year-old boy is referred for global developmental delay and "autistic features". He walked at 20 months and has fewer than ten single words. His mother's brother has intellectual disability and lives in supported accommodation. A previous paediatrician sent a chromosomal microarray, which returned normal. The parents ask why you are ordering more tests. [1] [5]
a) Explain why a normal chromosomal microarray does not exclude fragile X syndrome, and name the specific two-part molecular test you will order. (3 marks) [1] [5]
b) Define the four FMR1 CGG-repeat allele classes, giving the repeat boundaries and methylation status of each. (3 marks) [3] [5]
c) Outline the comorbidity-driven management plan for this child, naming four domains beyond the genetic result that require active surveillance and support. (2 marks) [1]
d) Describe the cascade-testing obligation to the wider family, including the premutation-associated conditions you would screen for in his mother. (2 marks) [1] [9]
References4ShowHide
- [1]Hersh JH, Saul RA Health supervision for children with fragile X syndrome. Pediatrics, 2011.PMID 21518720
- [3]Santoro MR, Bray SM, Warren ST. Molecular mechanisms of fragile X syndrome: a twenty-year perspective. Annu Rev Pathol, 2012.PMID 22017584
- [5]Pirozzi F, Tabolacci E, Neri G. The FRAXopathies: definition, overview, and update. Am J Med Genet A, 2011.PMID 21739597
- [9]Hagerman R, et al. Insight and recommendations for fragile X-premutation-associated conditions from the Fifth International Conference. Cells, 2023.PMID 37759552